FDA Approves New Drug for Lymphoma

Links shared publicly online about this topic.

  • 53
    total visits

FDA Approves New Drug for Lymphoma

webmd.com

The FDA has approved the drug Adcetris to treat two types of lymphoma, Hodgkin's lymphoma and a rare type of the disease known as systemic anaplastic large cell lymphoma (ALCL).

View full resource at webmd.com

Tags: Cancer, Lymphoma, Hodgkin Lymphoma, Disease and Condition, Drug, FDA, disease

  • Share

Most Recently Shared on August 22, 2011 at 6:23 pm By:

UCHealthNews UC Health

RT @webmd: FDA Approves New Drug for Lymphoma http://t.co/evvCAO6

8 months ago...

Also Shared By:

WebMD WebMD

New diet drug Qnexa awaits FDA approval amid safety questions – USATODAY.com

usatoday.com — “Some experts say it could potentially help dieters lose about 10% of their weight, but with its former FDA rejection, how safe is it?View full resource at usatoday.com

  • View Related
  • Share

Most Recently Shared on April 4, 2012 at 10:45 pm By:

USATODAYhealth Maureen Linke Health News

Diet drug Qnexa awaits FDA approval amid safety questions http://t.co/YjlUT7Bn

1 week ago...

Consumer Reports Warns of Lax Testing for Medical Devices - ABC News

abcnews.go.com — “Consumer Reports advises patients to do their homework before having medical devices implanted in their bodies.  Companies that sell defibrillators, stents or other such products can get approval from the Food and Drug Administration without their undergoing rigorous testing, Consumer Reports warned in a new report. The FDA collects information on medical device malfunctions that lead to death. Data highlighted by Consumer Reports show 686 deaths from 2009 to last year connected to automateView full resource at abcnews.go.com

  • View Related
  • Share

Most Recently Shared on March 29, 2012 at 7:39 pm By:

HITpol HealthIT Policy Health News and Health IT

Consumer Reports Warns of Lax Testing for Medical Devices: Consumer Reports advises patients to do their homewor... http://t.co/z5sM68RZ

2 weeks ago...

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 28, 2012 at 6:19 pm By:

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 28, 2012 at 1:16 am By:

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 27, 2012 at 7:30 pm By:

HealthTrendster HealthTrendster Health Executive

F.D.A. Approves New Anemia Drug - A new anemia drug provides a less expensive alternative for dialysis patients and ... http://t.co/9YfRzcyE

3 weeks ago...

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The F.D.A. approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 27, 2012 at 7:15 pm By:

Health_CK Catherine K Health Advocate

F.D.A. Approves New Anemia Drug: A new anemia drug provides a less expensive alternative for dialysis patients a... http://t.co/4Ku4AF4F

3 weeks ago...

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 27, 2012 at 6:27 pm By:

DrAnasYounes Anas Younes, M.D. Internist, Oncologist, Physician, and Doctor

F.D.A. Approves Affymax's new drug Omontys for anemic patients receiving kidney dialysis... http://t.co/2o68syVQ

3 weeks ago...

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 27, 2012 at 6:21 pm By:

Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen | Xconomy

xconomy.com — “Affymax completed its surprising comeback today, as it won FDA clearance for its first marketed drug, a product for anemia that will be the first to rival aView full resource at xconomy.com

  • View Related
  • Share

Most Recently Shared on March 27, 2012 at 4:58 pm By:

ldtimmerman Luke Timmerman Health Communicator

Update to Affymax FDA approval story, with comments from CEO John Orwin. Conf call coming later today. http://t.co/bG1ow9T0

3 weeks ago...

FDA approves Teva's QNASL nasal aerosol corticosteroid

news-medical.net — “Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on March 26, 2012 at 7:03 pm By:

asthma_news News-Medical.Net Health News

Asthma News: FDA approves Teva's QNASL nasal aerosol corticosteroid: Teva Pharmaceutical Industries Ltd. announc... http://t.co/2cZSMyF6

3 weeks ago...

FDA ponders need for heart studies ahead of drug approvals; New VC fund takes shape for Scotland; - FierceBiotech

fiercebiotech.com — “@FierceBiotech: Amgen's AMG 145 cuts cholesterol by 66% in early-stage trial involving patients taking statins. Article | Follow @FierceBiotech @JohnCFierce: Merck: I paid $41 billion for Read more...View full resource at fiercebiotech.com

  • View Related
  • Share

Most Recently Shared on March 26, 2012 at 4:57 pm By:

carybyrd Cary Byrd - eDrugSearch.com Pharma and Health Advocate

FDA ponders need for heart studies ahead of drug approvals; New VC fund takes shape for Scotland; - FierceBiotech http://t.co/bpFa4yK5

3 weeks ago...

Experts challenge FDA over approval for new dose of Alzheimer's drug | Science Codex

sciencecodex.com — “Approval for a new dose of a best-selling Alzheimer's drug "breached the FDA's own regulatory standard" and has led to "incomplete and distorted messages" about the drug, warn experts on bmj.com today. In the first of a new occasionalView full resource at sciencecodex.com

  • View Related
  • Share

Most Recently Shared on March 23, 2012 at 11:58 am By:

sarasteinmd Sara Stein MD Physician, Doctor, and Psychiatrist

#Dementia Pharma at its worst again, distorted advertising on Aricept to get you buying the new name brand version... http://t.co/puM4CgEj

3 weeks ago...

Experts challenge FDA over approval for new dose of Alzheimer?s drug

alzheimersreadingroom.com — “Experts challenge FDA over approval for new dose of Alzheimer?s drugView full resource at alzheimersreadingroom.com

  • View Related
  • Share

Most Recently Shared on March 23, 2012 at 2:55 am By:

ALZHEIMERSreadAlzheimer's Reading Room is the number one source of life news for the entire Alzheimer's community. Our goal is to Educate, sometimes Entertain, and Empower Alzheimers caregivers and their families worldwide.


" /> Alzheimer's Reading Room Health Advocate

http://t.co/cd0mwZ54 http://t.co/8NsUVoCU

3 weeks ago...

Experts challenge FDA over approval for new dose of Alzheimer?s drug

alzheimersreadingroom.com — “Experts challenge FDA over approval for new dose of Alzheimer?s drugView full resource at alzheimersreadingroom.com

  • View Related
  • Share

Most Recently Shared on March 23, 2012 at 2:54 am By:

ALZHEIMERSreadAlzheimer's Reading Room is the number one source of life news for the entire Alzheimer's community. Our goal is to Educate, sometimes Entertain, and Empower Alzheimers caregivers and their families worldwide.


" /> Alzheimer's Reading Room Health Advocate

Experts challenge FDA over approval for new dose of Alzheimerʼs drug: Approval for a new dose ... http://t.co/82oiq3Ol #alzheimers #news

3 weeks ago...

Experts challenge FDA over approval for new dose of Alzheimer?s drug

alzheimersreadingroom.com — “Experts challenge FDA over approval for new dose of Alzheimer?s drugView full resource at alzheimersreadingroom.com

  • View Related
  • Share

Most Recently Shared on March 23, 2012 at 2:54 am By:

BobbyDelray Bob DeMarco Patient Advocate

BobbyDelray: Experts challenge FDA over approval for new dose of Alzheimerʼs drug http://t.co/SyLe3Lrd

3 weeks ago...

Advertisement